海格投资 HTGC 深 沪
等待开盘 04-02 09:30:00 美东时间
14.56
-0.210
-1.42%
华盛通- 最 高14.85
- 今 开14.79
- 成交量 210.32万股
- 最 低 14.46
- 昨 收 14.77
- 总市值 26.75亿
- 52周最高 18.68
- 市盈率 静 7.85
- 换手率 1.14%
- 52周最低 13.7001
- 委 比 78.73%
- 总股本 1.84亿
- 历史最高 19.69
- 量 比 0.86
- 振 幅 2.64%
- 历史最低 -5.25
- 每 手 1
- 风险率 1.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
UBS Maintains Neutral on Hercules Capital, Lowers Price Target to $15
UBS analyst Vilas Abraham maintains Hercules Capital (NYSE:HTGC) with a Neutral and lowers the price target from $19.5 to $15.
03-14 04:16
Private credit stress grows as Quant ratings turn cautious on several firms
Concerns are mounting across the roughly $2T private credit market after a series of recent credit issues and fund restrictions put the fast-growing sector under fresh scrutiny, pressuring shares of s...
03-12 21:24
Top 3 Financial Stocks That May Explode In March
Oversold stocks in financial sector present buying opportunity. RSI indicator compares strength of stock on up & down days, below 30 is oversold.
03-04 19:05
Hercules Capital CEO Scott Bluestein Acquires Common Shares
Hercules Capital CEO Scott Bluestein Acquires Common Shares Scott Bluestein, Chief Executive Officer of Hercules Capital Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologi
02-25 07:54
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
MoonLake Immunotherapeutics announced positive topline results from its Phase 2 S-OLARIS trial of sonelokimab (SLK) in axial spondyloarthritis (axSpA), with over 80% of patients achieving ASAS40 and significant reductions in inflammation and bone formation. Financially, the company ended Q4 2025 with $394 million in cash, plus $75 million from an equity raise, providing a runway to H2 2027. An Investor Day is scheduled for Feb 23, 2026, featuring...
02-22 16:00
BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk,
BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk, Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks rose in volatile trading on Friday as inflation showed signs of cooling, but
02-14 02:35
BUZZ-Hercules Capital falls after earnings miss estimates
BUZZ-Hercules Capital falls after earnings miss estimates ** Shares of business development company Hercules Capital HTGC.N fall 6.2% to $15.57 ** Co posted net investment income of $87 million or 48 cents per share on Thursday, below analysts' estimates of $91 million or 49 cents per share ** Piper
02-14 00:27
Piper Sandler Downgrades Hercules Capital to Neutral, Lowers Price Target to $17.5
Piper Sandler analyst Crispin Love downgrades Hercules Capital (NYSE:HTGC) from Overweight to Neutral and lowers the price target from $20.5 to $17.5.
02-13 18:10
U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Gilead
U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Gilead Feb 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, Humana and Gilead, on Friday. HIGHLIGHTS * 10X Genomics Inc TXG.O : JP Morgan raises targe
02-13 14:43
